Search for drugs:
Typing the drug name to query
DARUNAVIR
DIR Classification
Classification:Moderate-DIQT concern
Severity Score:3.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- DRUG INTERACTIONS
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- In a thorough QT/QTc study in 40 healthy subjects, PREZISTA/ritonavir doses of 1.33 times the maximum recommended dose did not affect the QT/QTc interval.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
15
24077
Other ADRs
8498
38373089
Odds Ratio = 2.814
Drug Property Information
ATC Code(s):
- J05AE10 - darunavir
- J05AE - Protease inhibitors
- J05A - DIRECT ACTING ANTIVIRALS
- J05 - ANTIVIRALS FOR SYSTEMIC USE
- J - ANTIINFECTIVES FOR SYSTEMIC USE
Active Ingredient:darunavir ethanolate
Active Ingredient UNII:33O78XF0BW
Drugbank ID:DB01264
PubChem Compound:213039
CTD ID: D000069454
PharmGKB:PA163522472
CAS Number:206361-99-1
Dosage Form(s):suspension; tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 1200.0 mg/day J05AE10
Chemical Structure: 
SMILE Code:
[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Reference
1: Pharmacogenomics of COVID-19 therapies.
[Takahashi Takuto,Luzum Jasmine A,Nicol Melanie R,Jacobson Pamala A]NPJ Genom Med,2020 Aug 18;5:35. PMID: 32864162
2: Early experience with remdesivir in SARS-CoV-2 pneumonia.
[Durante-Mangoni Emanuele,Andini Roberto,Bertolino Lorenzo,Mele Ferruccio,Florio Letizia Lucia,Murino Patrizia,Corcione Antonio,Zampino Rosa]Infection,2020 Oct;48(5):779-782. PMID: 32418190
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.